Efficacy and Safety of the Intratracheal Administration of Budesonide With Porcine Pulmonary Surfactant in Very Preterm Infants to Prevent Bronchopulmonary Dysplasia: Randomized Clinical Trial (BuS Trial)
Latest Information Update: 25 Sep 2021
Price :
$35 *
At a glance
- Drugs Poractant alfa (Primary) ; Budesonide
- Indications Bronchopulmonary dysplasia; Neonatal respiratory distress syndrome
- Focus Biomarker; Therapeutic Use
- Acronyms BuS
- 06 Sep 2021 Planned End Date changed from 15 Nov 2025 to 1 Apr 2026.
- 06 Sep 2021 Planned primary completion date changed from 15 Nov 2023 to 1 Apr 2024.
- 06 Sep 2021 Planned initiation date changed from 15 May 2021 to 1 Oct 2021.